Nanoform Finland Plc (NANOFH) - Total Liabilities

Latest as of September 2025: €12.56 Million EUR ≈ $14.68 Million USD

Based on the latest financial reports, Nanoform Finland Plc (NANOFH) has total liabilities worth €12.56 Million EUR (≈ $14.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Nanoform Finland Plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Nanoform Finland Plc - Total Liabilities Trend (2016–2024)

This chart illustrates how Nanoform Finland Plc's total liabilities have evolved over time, based on quarterly financial data. Check NANOFH asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Nanoform Finland Plc Competitors by Total Liabilities

The table below lists competitors of Nanoform Finland Plc ranked by their total liabilities.

Company Country Total Liabilities
ICE FISH FARM AS NK-10
F:4YYA
Germany €228.30 Million
Kootenay Silver Inc
V:KTN
Canada CA$361.85K
Asia Pacific Satellite Inc
KQ:211270
Korea ₩22.41 Billion
Fortune Parts Industry Public Company Limited
BK:FPI
Thailand ฿1.88 Billion
JW Shinyak Corporation
KQ:067290
Korea ₩26.02 Billion
Alcadon Group AB
ST:ALCA
Sweden Skr737.80 Million
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
USA $416.00K
NICE Total Cash Management Co. Ltd
KQ:063570
Korea ₩471.11 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Nanoform Finland Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nanoform Finland Plc (NANOFH) total assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanoform Finland Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanoform Finland Plc (2016–2024)

The table below shows the annual total liabilities of Nanoform Finland Plc from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €11.77 Million
≈ $13.77 Million
+5.24%
2023-12-31 €11.19 Million
≈ $13.08 Million
-16.69%
2022-12-31 €13.43 Million
≈ $15.70 Million
-9.63%
2021-12-31 €14.86 Million
≈ $17.37 Million
+32.07%
2020-12-31 €11.25 Million
≈ $13.15 Million
+126.01%
2019-12-31 €4.98 Million
≈ $5.82 Million
+56.78%
2018-12-31 €3.18 Million
≈ $3.71 Million
+205.34%
2017-12-31 €1.04 Million
≈ $1.22 Million
+82.31%
2016-12-31 €570.41K
≈ $666.87K
--

About Nanoform Finland Plc

HE:NANOFH Finland Biotechnology
Market Cap
$77.32 Million
€66.14 Million EUR
Market Cap Rank
#20263 Global
#95 in Finland
Share Price
€0.77
Change (1 day)
+0.00%
52-Week Range
€0.42 - €1.23
All Time High
€8.50
About

Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more